[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657974":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":22,"studyPopulation":22,"armGroups":35,"interventions":49,"overallOfficials":62,"centralContacts":66,"locations":72,"responsibleParty":85,"collaborators":22,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":22,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":22,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":22,"overallStatus":107,"whyStopped":22,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"AUC,para: The area under the paracetamol plasma concentration-time curve following a standardised meal","Measured in hour micrograms per millilitre (h\\*µg\u002FmL).","Day 177",[14,16,19],{"measure":10,"description":15,"timeFrame":12},"Measured in h\\*μg\u002FmL.",{"measure":17,"description":18,"timeFrame":12},"Cmax,para; Maximum observed paracetamol plasma concentration following a standardised meal","Measured in microgram per millilitre (μg\u002FmL).",{"measure":20,"description":21,"timeFrame":12},"tmax;para: Time to maximum observed paracetamol plasma concentration","Measured in hours.",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":28,"maskingDescription":29,"whoMasked":30},"QUADRUPLE","Sponsor staff involved in the clinical trial is masked according to company standard procedures.",[31,32,33,34],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[36,43],{"label":37,"type":38,"description":39,"interventionNames":40},"Semaglutide","EXPERIMENTAL","Participants will receive semaglutide administered subcutaneously once weekly at multiple dose levels.",[41,42],"Drug: Semaglutide","Drug: Paracetamol",{"label":44,"type":45,"description":46,"interventionNames":47},"Placebo","PLACEBO_COMPARATOR","Participants will receive placebo matched semaglutide administered subcutaneously once weekly at multiple dose levels.",[48,42],"Drug: Placebo semaglutide",[50,54,58],{"type":51,"name":37,"description":52,"armGroupLabels":53,"otherNames":22},"DRUG","Semaglutide will be administered in the thigh, abdomen, or upper arm of body part.",[37],{"type":51,"name":55,"description":56,"armGroupLabels":57,"otherNames":22},"Placebo semaglutide","Placebo matched to semaglutide will be administered in the thigh, abdomen, or upper arm of body part.",[44],{"type":51,"name":59,"description":60,"armGroupLabels":61,"otherNames":22},"Paracetamol","Paracetamol is administered orally as part of a standardised meal to assess gastric emptying through pharmacokinetic evaluation.",[44,37],[63],{"name":64,"affiliation":5,"role":65},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[67],{"name":68,"role":69,"phone":70,"phoneExt":22,"email":71},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[73],{"facility":74,"status":22,"city":75,"state":22,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":22},"Medical University of Graz","Graz","8010","Austria","AT",{"type":80,"coordinates":81},"Point",[82,83],15.44197,47.06733,{"lat":83,"lon":82},{"type":86,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100657974","phase-1-a-research-study-looking-into-how-a-high-dose-of-sc-semaglutide-works-with-emptying-of-the-stomach-in-people-with-excess-body-weight-100657974",false,"NCT07845578","A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight","An Investigation of the Effect of High Dose s.c. Semaglutide on Gastric Emptying in Participants With Obesity","Inclusion Criteria:\n\n* Age 18-64 years (both inclusive) at the time of signing the informed consent.\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Body mass index (BMI) between 30.0 - 44.9 kilogram per meter square (kg\u002Fm\\^2) (both inclusive) at screening. Obesity should be due to excess adipose tissue, as judged by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) (including paracetamol) or related products.\n* Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval) and occasional use of paracetamol\u002Facetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation.\n* Impaired liver function defined as any of the below:\n\n  1. Alanine Aminotransferase (ALT) greater than or equal to (\\>= ) 2.5 times the upper limit of normal (ULN)\n  2. Aspartate Aminotransferase (AST) \\>=2.5 times ULN\n  3. Total bilirubin greater than (\\>) 1.5 times ULN","ALL","18 Years","64 Years",{"count":98,"type":99},60,"ESTIMATED","INTERVENTIONAL",[102],"PHASE1","The purpose of the study is to determine the effect of semaglutide on gastric emptying in people with obesity. Participants will receive either semaglutide or placebo, and the treatment assigned will be decided by chance. Semaglutide is a medicine that doctors can already prescribe, while placebo contains no active medicine.",[105,106],"Obesity","Overweight","NOT_YET_RECRUITING","2026-09-22",{"date":110,"type":111},"2026-09-29","ACTUAL",{"date":113,"type":99},"2026-09-25",{"date":115,"type":99},"2027-09-11",{"name":5,"class":6},1]